期刊
BLOOD
卷 122, 期 24, 页码 3863-3870出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-07-514448
关键词
-
类别
资金
- National Cancer Institute [U24- CA76518, HHSH234200637015C]
- National Heart, Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung and Blood Institute [5U01HL069294]
- Health Resources and Services Administration (HRSA/DHHS)
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- Allos, Inc.
- Amgen, Inc.
- Angioblast
- Ariad
- Be the Match Foundation
- Blue Cross
- Blue Shield Association
- Buchanan Family Foundation
- CaridianBCT
- Celgene Corporation
- CellGenix
- GmbH
- Children's Leukemia Research Association
- Fresenius-Biotech North America, Inc.
- Gamida Cell Teva Joint Venture Ltd.
- Genentech, Inc.
- Genzyme Corporation
- GlaxoSmithKline
- Kiadis Pharma
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Millennium Pharmaceuticals, Inc.
- Milliman USA, Inc.
- Miltenyi Biotec, Inc.
- National Marrow Donor Program
- Optum Healthcare Solutions, Inc.
- Otsuka America Pharmaceutical, Inc.
- Seattle Genetics
- Sigma-tau Pharmaceuticals
- Soligenix, Inc.
- Swedish Orphan Biovitrum
- THERAKOS, Inc.
- Wellpoint, Inc.
Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are the most widely used myeloablative conditioning regimens for allotransplants. Recent data regarding their comparative effectiveness are lacking. We analyzed data from the Center for International Blood and Marrow Transplant Research for 1230 subjects receiving a first hematopoietic cell transplant from a human leukocyte antigen-matched sibling or from an unrelated donor during the years 2000 to 2006 for acute myeloid leukemia (AML) in first complete remission (CR) after conditioning with Cy/TBI or oral or intravenous (IV) BuCy. Multivariate analysis showed significantly less nonrelapse mortality (relative risk [RR] = 0.58; 95% confidence interval [CI]: 0.39-0.86; P = .007), and relapse after, but not before, 1 year posttransplant (RR = 0.23; 95% CI: 0.08-0.65; P = .006), and better leukemia-free survival (RR = 0.70; 95% CI: 0.55-0.88; P = .003) and survival (RR = 0.68; 95% CI: 0.52-0.88; P = .003) in persons receiving IV, but not oral, Bu compared with TBI. In combination with Cy, IV Bu is associated with superior outcomes compared with TBI in patients with AML in first CR. (Blood. 2013;122(24):3863-3870)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据